Trevi Therapeutics, Inc. today announced positive interim analysis results of the Phase 2 Cough And NALbuphine (CANAL) trial of its investigational therapy Haduvio™ (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF) suffering from chronic cough, establishing proof of concept. Further patient recruitment in the trial will stop based on the strength and consistency of the…

eTurboNews Els articles són només per a subscriptors. La subscripció és GRATIS.
Els subscriptors inicien sessió aquí Feu clic aquí per subscriure-us GRATIS

QUÈ TREURE D'AQUEST ARTICLE:

Further patient recruitment in the trial will stop based on the strength and consistency of the….
today announced positive interim analysis results of the Phase 2 Cough And NALbuphine (CANAL) trial of its investigational therapy Haduvio™ (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF) suffering from chronic cough, establishing proof of concept.
La subscripció és GRATUÏTA.